Source Paper
Source Paper
Journal of Neuroscience • 1999
Using immunocytochemistry and ELISA, we investigated the production of interleukin (IL)-1β in the rat hippocampus after focal application of kainic acid inducing electroencephalographic (EEG) seizures and CA3 neuronal cell loss. Next, we studied whether EEG seizures per se induced IL-1β and microglia changes in the hippocampus using bicuculline as a nonexcitotoxic convulsant agent. Finally, to address the functional role of this cytokine, we measured the effect of human recombinant (hr)IL-1β on seizure activity as one marker of the response to kainate. Three and 24 hr after unilateral intrahippocampal application of 0.19 nmol of kainate, IL-1β immunoreactivity was enhanced in glia in the injected and the contralateral hippocampi. At 24 hr, IL-1β concentration increased by 16-fold ( p < 0.01) in the injected hippocampus. Reactive microglia was enhanced with a pattern similar to IL-1β immunoreactivity. Intrahippocampal application of 0.77 nmol of bicuculline methiodide, which induces EEG seizures but not cell loss, enhanced IL-1β immunoreactivity and microglia, although to a less extent and for a shorter time compared with kainate. One nanogram of (hr)IL-1β intrahippocampally injected 10 min before kainate enhanced by 226% the time spent in seizures ( p < 0.01). This effect was blocked by coinjection of 1 µg (hr)IL-1β receptor antagonist or 0.1 ng of 3-((+)-2-carboxypiperazin-4-yl)-propyl-1-phosphonate, selective antagonists of IL-1β and NMDA receptors, respectively. Thus, convulsant and/or excitotoxic stimuli increase the production of IL-1β in microglia-like cells in the hippocampus. In addition, exogenous application of IL-1β prolongs kainate-induced hippocampal EEG seizures by enhancing glutamatergic neurotransmission.
Objective: Measure the effect of exogenous human recombinant IL-1β on kainate-induced seizure duration and determine if IL-1β receptor antagonist and NMDA receptor antagonist can block this effect
This is a IL-1β Functional Effect on Seizure Duration protocol using rat as the model organism. The procedure involves 7 procedural steps, 1 equipment items, 5 materials. Extracted from a 1999 paper published in Journal of Neuroscience.
Model and subjects
rat • Not specified • unknown • Not specified • Not specified
Study window
~1 day study window | ~24.5 hours hands-on
Core workflow
Baseline assessment and animal preparation • Intrahippocampal injection of human recombinant IL-1β • Intrahippocampal injection of kainate
Primary readouts
Key equipment and reagents
Verified items
0
Direct vendor links
0
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
Use the page like this
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Prepare rats for intrahippocampal injection procedure
Note: Unilateral intrahippocampal injection approach used
“unilateral intrahippocampal application of 0.19 nmol of kainate”
Inject 1 nanogram of hrIL-1β intrahippocampally 10 minutes before kainate injection
Note: Timing is critical - must be 10 minutes prior to kainate
“One nanogram of (hr)IL-1β intrahippocampally injected 10 min before kainate”
Inject 0.19 nmol of kainic acid intrahippocampally to induce seizures
Note: This is the primary convulsant stimulus
“Three and 24 hr after unilateral intrahippocampal application of 0.19 nmol of kainate”
Record electroencephalographic activity to measure seizure duration and electrographic seizures
Note: Seizure duration is the primary outcome measure
“we measured the effect of human recombinant (hr)IL-1β on seizure activity as one marker of the response to kainate”
Coinjection of 1 µg hrIL-1β receptor antagonist with hrIL-1β to determine if IL-1β effects are blocked
Note: Coinjection approach used to test blocking effects
“This effect was blocked by coinjection of 1 µg (hr)IL-1β receptor antagonist”
Coinjection of 0.1 ng of 3-((+)-2-carboxypiperazin-4-yl)-propyl-1-phosphonate with hrIL-1β to determine if NMDA receptor antagonism blocks IL-1β effects
Note: Selective NMDA receptor antagonist used
“or 0.1 ng of 3-((+)-2-carboxypiperazin-4-yl)-propyl-1-phosphonate, selective antagonists of IL-1β and NMDA receptors, respectively”
Collect hippocampal tissue at 3 and 24 hours after kainate injection for analysis of IL-1β immunoreactivity and concentration
Note: Both injected and contralateral hippocampi collected
“Three and 24 hr after unilateral intrahippocampal application of 0.19 nmol of kainate, IL-1β immunoreactivity was enhanced”
This section explains what the experiment is doing, which readouts matter, what the data artifacts usually look like, and how the analysis should flow from raw capture to reported result.
Measure the effect of exogenous human recombinant IL-1β on kainate-induced seizure duration and determine if IL-1β receptor antagonist and NMDA receptor antagonist can block this effect
Objective
Measure the effect of exogenous human recombinant IL-1β on kainate-induced seizure duration and determine if IL-1β receptor antagonist and NMDA receptor antagonist can block this effect
Subjects
From paperrat • Not specified • unknown • Not specified • Not specified
Cohort notes
From paperUnilateral intrahippocampal injection procedure performed
Baseline assessment and animal preparation (Not specified)
Intrahippocampal injection of human recombinant IL-1β (10 minutes before kainate injection)
Intrahippocampal injection of kainate (Not specified)
EEG recording and seizure monitoring (Not specified)
Seizure duration (time spent in seizures)
From paperStatistical analysis performed with p-values reported (p < 0.01 for IL-1β concentration increase of 16-fold and seizure duration increase of 226%)
Artifact type
Endpoint measurements summarized by group or timepoint
Comparison focus
Compare endpoint magnitude between groups, timepoints, or both
EEG seizure activity (electrographic seizures)
From paperStatistical analysis performed with p-values reported (p < 0.01 for IL-1β concentration increase of 16-fold and seizure duration increase of 226%)
Artifact type
Endpoint measurements summarized by group or timepoint
Comparison focus
Compare endpoint magnitude between groups, timepoints, or both
IL-1β immunoreactivity in hippocampus
From paperStatistical analysis performed with p-values reported (p < 0.01 for IL-1β concentration increase of 16-fold and seizure duration increase of 226%)
Artifact type
Endpoint measurements summarized by group or timepoint
Comparison focus
Compare endpoint magnitude between groups, timepoints, or both
IL-1β concentration (measured by ELISA)
From paperStatistical analysis performed with p-values reported (p < 0.01 for IL-1β concentration increase of 16-fold and seizure duration increase of 226%)
Artifact type
Endpoint measurements summarized by group or timepoint
Comparison focus
Compare endpoint magnitude between groups, timepoints, or both
Seizure duration (time spent in seizures)
From paperRaw artifact
Per-sample or per-animal endpoint measurements collected during the experiment
Processed artifact
Structured table with cleaned measurements ready for comparison
Final reported form
Summary statistics and between-group or across-timepoint comparisons
EEG seizure activity (electrographic seizures)
From paperRaw artifact
Per-sample or per-animal endpoint measurements collected during the experiment
Processed artifact
Structured table with cleaned measurements ready for comparison
Final reported form
Summary statistics and between-group or across-timepoint comparisons
IL-1β immunoreactivity in hippocampus
From paperRaw artifact
Per-sample or per-animal endpoint measurements collected during the experiment
Processed artifact
Structured table with cleaned measurements ready for comparison
Final reported form
Summary statistics and between-group or across-timepoint comparisons
IL-1β concentration (measured by ELISA)
From paperRaw artifact
Per-sample or per-animal endpoint measurements collected during the experiment
Processed artifact
Structured table with cleaned measurements ready for comparison
Final reported form
Summary statistics and between-group or across-timepoint comparisons
Acquisition
Collect raw experimental outputs with enough metadata to preserve sample identity, condition, and timing.
Preprocessing / cleaning
Statistical analysis performed with p-values reported (p < 0.01 for IL-1β concentration increase of 16-fold and seizure duration increase of 226%)
Scoring or quantification
Quantify the primary readouts for this experiment: Seizure duration (time spent in seizures); EEG seizure activity (electrographic seizures); IL-1β immunoreactivity in hippocampus; IL-1β concentration (measured by ELISA).
Statistical comparison
Statistical method not yet structured for this page.
Reporting output
Report representative outputs alongside summary comparisons for Seizure duration (time spent in seizures), EEG seizure activity (electrographic seizures), IL-1β immunoreactivity in hippocampus, IL-1β concentration (measured by ELISA).
Source links and direct wording from the methods section for validation and deeper review.
Citation
Annamaria Vezzani et al. (1999). Interleukin-1β Immunoreactivity and Microglia Are Enhanced in the Rat Hippocampus by Focal Kainate Application: Functional Evidence for Enhancement of Electrographic Seizures. Journal of Neuroscience
“”
“”
“”
“”
Direct vendor pages are linked from the protocol above. This section stays focused on the full comparison view and the prep checklist.
Gather these items before starting the experiment. Check off items as you prepare.
Not specified • Not specified • Not specified • Not specified
Not specified • Not specified • Not specified • Not specified
Not specified • Not specified • Not specified • Not specified
Not specified • Not specified • Not specified • Not specified
Not specified • Not specified • Not specified • Not specified
Not specified • Not specified • Not specified • Not specified
Not specified • Not specified
Use this section as the page quality checkpoint. It keeps section navigation, evidence access, readiness, and verification meaning in one place.
Current status surfaces were computed from experiment data updated Feb 28, 2026.
Source access
Jump back into the original paper or the methods evidence section when you need exact wording, exclusions, or method-specific caveats.
This protocol has structured steps plus evidence quotes, and is ready for canonical sync.
Steps
7
Evidence Quotes
13
Protocol Items
6
Linked Products
0
Canonical Sync
Pending
What this means
The completeness score reflects how much structured protocol data is present: steps, methods evidence, listed materials, linked products, and paper provenance.
Computed from the current experiment record updated Feb 28, 2026.
Canonical Sync shows whether a ConductGraph-backed protocol is available for this experiment route right now. It is a sync-status signal, not a claim that every downstream vendor link or step detail is perfect.
Steps
7
Evidence
13
Specific Products
0/0
Canonical Sync
Pending
What this score means
The verification score reflects evidence coverage, subject detail, paper provenance, step depth, and whether linked products resolve to specific item pages instead of generic searches.
Computed from the current experiment record updated Feb 28, 2026.
A page can have structured steps and still need review when evidence is thin, product links are generic, or canonical protocol coverage is still pending.
What still needs work